|
⚲
|
| Keyboard |
| Marc Tessier-Lavigne | |
|---|---|
| Firm | |
| Address | c/o Denali Therapeutics Inc 161 Oyster Point Blvd South San Francisco, CA 94080 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Denali Therapeutics Inc | 021-506551 | Director | 499.7 M of 499.7 M |
||
| Juno Therapeutics Inc | 021-243722 | Director | 898.5 M | ||
| Juno Therapeutics Inc | 021-222931 | Director | 85.5 M of 133.7 M |
||
| Juno Therapeutics Inc | 021-217030 | Director | 28.4 M of 97.0 M |
||
| Agios Pharmaceuticals Inc | 021-169115 | Director | 78.0 M of 78.0 M |
||